Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

PHASE2CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

February 28, 2013

Conditions
GoutHyperuricemiaArthritisJoint Disease
Interventions
DRUG

ulodesine

Oral dose administered daily for 84 days.

DRUG

Placebo

Oral dose administered daily for 84 days.

Trial Locations (54)

Unknown

Birmingham

Mobile

Phoenix

Scottsdale

Tucson

Malvern

Anaheim

Burbank

Irvine

La Mesa

Los Angeles

Oceanside

Palm Springs

Paramount

Sacramento

San Jose

Walnut Creek

West Covina

DeLand

Edgewater

Gainesville

Miami

Oldsmar

Sanford

Atlanta

Honolulu

Meridian

Gurnee

Brownsburg

Newton

Lexington

Baltimore

Springfield

Lansing

Olive Branch

Omaha

Albuquerque

Charlotte

Greensboro

Raleigh

Salisbury

Winston-Salem

Cincinnati

Cleveland

Oklahoma City

Duncansville

Greer

Rapid City

Bristol

Dallas

San Antonio

Salt Lake City

Richmond

Tacoma

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY